Why Is Long-Term Therapy Required to Cure Tuberculosis?

The authors argue that understanding and countering general bacterial mechanisms of phenotypic antibiotic resistance may hold the key to reducing the duration of treatment of all recalcitrant bacterial infections, including tuberculosis.

• Publication year

  2007

• Venue

  PLoS Medicine

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1371/journal.pmed.0040120PMID 17388672PMCID 1831743
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months.

  2015cited by this paper
• Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies.

  2015cited by this paper
• Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.

  2015cited by this paper
• The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

  2015cited by this paper
• Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.

  2015cited by this paper
• Persister cells, dormancy and infectious disease

  2007cited by this paper
• Microbial phenotypic heterogeneity and antibiotic tolerance.

  2007cited by this paper
• New strategies for antibacterial drug design: targeting non-multiplying latent bacteria.

  2006cited by this paper
• Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy

  2006cited by this paper
• Prospects for Advancing Tuberculosis Control Efforts through Novel Therapies

  2006cited by this paper
• Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

  2006cited by this paper
• New Strategies for Antibacterial Drug Design

  2006cited by this paper
• Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance

  2006cited by this paper
• Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.

  2006cited by this paper
• Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs.

  2006cited by this paper
• The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells

  2006cited by this paper
• Characterization of mRNA Interferases from Mycobacterium tuberculosis*

  2006cited by this paper
• Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

  2006cited by this paper
• Non-inherited antibiotic resistance

  2006cited by this paper
• Persisters: a distinct physiological state of E. coli

  2006cited by this paper
• Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in Mycobacteria

  2006cited by this paper
• Replication Dynamics of Mycobacterium tuberculosis in Chronically Infected Mice

  2005cited by this paper
• Phenotypic Tolerance: Antibiotic Enrichment of Noninherited Resistance in Bacterial Populations

  2005cited by this paper
• The diagnosis and therapy of tuberculosis during the past 100 years.

  2005cited by this paper
• Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.

  2005cited by this paper
• Exogenous reinfection in tuberculosis.

  2005cited by this paper
• Tuberculosis — metabolism and respiration in the absence of growth

  2005cited by this paper
• Corticosteroids and Endothelial Dysfunction

  2005cited by this paper
• The PIN-domain toxin-antitoxin array in mycobacteria.

  2005cited by this paper
• Toxin-antitoxin modules as bacterial metabolic stress managers.

  2005cited by this paper
• Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase Cultures of Mycobacterium tuberculosis

  2005cited by this paper
• A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

  2005cited by this paper
• Modelling protection from antimicrobial agents in biofilms through the formation of persister cells.

  2005cited by this paper
• Persister cells and the riddle of biofilm survival

  2005cited by this paper
• Prokaryotic toxin–antitoxin stress response loci

  2005cited by this paper
• Faculty Opinions recommendation of SOS response induction by beta-lactams and bacterial defense against antibiotic lethality.

  2004cited by this paper
• Bacterial Persistence as a Phenotypic Switch

  2004cited by this paper
• A Subinhibitory Concentration of Clarithromycin Inhibits Mycobacterium avium Biofilm Formation

  2004cited by this paper
• M. tuberculosis persistence, latency, and drug tolerance.

  2004cited by this paper
• Specialized Persister Cells and the Mechanism of Multidrug Tolerance in Escherichia coli

  2004cited by this paper
• Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy.

  2004cited by this paper
• SOS Response Induction by ß-Lactams and Bacterial Defense Against Antibiotic Lethality

  2004cited by this paper
• Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis

  2003cited by this paper
• Characterization of the hipA7 allele of Escherichia coli and evidence that high persistence is governed by (p)ppGpp synthesis

  2003cited by this paper
• The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice

  2003cited by this paper
• Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program

  2003cited by this paper
• Isoniazid resistance of exponentially growing Mycobacterium smegmatis biofilm culture.

  2003cited by this paper
• Treatment of tuberculosis.

  2003cited by this paper
• Mycobacterium tuberculosis Growth at theCavity Surface: a Microenvironment with FailedImmunity

  2003cited by this paper
• Mycobacterium bovis BCG Response Regulator Essential for Hypoxic Dormancy

  2002cited by this paper
• Mechanisms of antibiotic resistance in bacterial biofilms.

  2002cited by this paper
• Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.

  2002cited by this paper
• Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin.

  2001cited by this paper
• Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin

  2001cited by this paper
• Biofilms and Planktonic Cells of Pseudomonas aeruginosa Have Similar Resistance to Killing by Antimicrobials

  2001cited by this paper
• Tuberculosis: Latency and Reactivation

  2001cited by this paper
• Antibiotic Persistence: The Role of Spontaneous DNA Repair Response

  2001cited by this paper
• Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection.

  2000cited by this paper
• Drug Tolerance in Mycobacterium tuberculosis

  1999cited by this paper
• Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.

  1999cited by this paper
• Bacterial biofilms: a common cause of persistent infections.

  1999cited by this paper
• Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications.

  1999cited by this paper
• STREPTOMYCIN TREATMENT OF PULMONARY TUBERCULOSIS

  1998cited by this paper
• Mechanisms of latency in Mycobacterium tuberculosis.

  1998cited by this paper
• [Treatment of tuberculosis].

  1997cited by this paper
• Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients.

  1996cited by this paper
• Effectiveness of Cloxacillin with and without Gentamicin in Short-Term Therapy for Right-Sided Staphylococcus aureus Endocarditis

  1996cited by this paper
• Pulmonary tuberculosis in HIV-infected patients in Zaire

  1996cited by this paper
• Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis

  1996cited by this paper
• In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis

  1996cited by this paper
• Intraphagocytic growth induces an antibiotic-resistant phenotype of Legionella pneumophila

  1995cited by this paper
• Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months.

  1995cited by this paper
• Short-Course Antibiotic Therapy for Right-Sided Endocarditis Caused by Staphylococcus aureus in Injection Drug Users

  1994cited by this paper
• Counts of viable tubercle bacilli in sputum related to smear and culture gradings.

  1992cited by this paper
• Counts of viable tubercle bacilli in sputum related to smear and culture gradings.

  1992cited by this paper
• Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations.

  1992cited by this paper
• Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research

  1991cited by this paper
• Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

  1990cited by this paper
• Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents

  1990cited by this paper
• Short-term treatment of uncomplicated lower urinary tract infections in women.

  1990cited by this paper
• A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.

  1989cited by this paper
• Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy.

  1989cited by this paper
• Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.

  1988cited by this paper
• Staphylococcus aureus bacteremia.

  1987cited by this paper
• Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council.

  1987cited by this paper
• Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.

  1986cited by this paper
• Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy.

  1985cited by this paper
• Efficacy of various duration of isoniazid preventive therapy for tuberculosis : five years follow-up in the IUAT trial

  1982cited by this paper
• Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.

  1982cited by this paper
• Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study.

  1982cited by this paper
• Basic mechanisms of chemotherapy.

  1979cited by this paper
• Staphylococcus aureus bacteremia: Current clinical patterns

  1976cited by this paper
• Enumeration of Tubercle Bacilli in Sputum of Patients with Pulmonary Tuberculosis

  1973cited by this paper
• TIMETABLE OF TUBERCULOSIS

  1972cited by this paper
• Exogenous reinfection in tuberculosis.

  1970cited by this paper
• Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis.

  1970cited by this paper
• Microbial persistence.

  1969cited by this paper
• Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts.

  1961cited by this paper
• Microbial Persistence **

  1958cited by this paper
• THE TREATED PULMONARY LESION AND ITS TUBERCLE BACILLUS.*: II. THE DEATH AND RESURRECTION

  1956cited by this paper

• Granuloma dual RNA-seq reveals composite transcriptional programs driven by neutrophils and necrosis within tuberculous granulomas

  2026cites this paper
• Digital twin of Mycobacterium tuberculosis infection: Integrating immune dynamics and pathogen adaptation for precision therapy.

  2026cites this paper
• Partial Resolution of Unilateral Tuberculous Lung Destruction: A Case Report of a 13‐Years Old Patient

  2025cites this paper
• Ten‐Day Versus 14‐Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial

  2025cites this paper
• Conquering the tuberculosis Superbug: Innovative approaches for biofilm disruption and antibiotic resistance mitigation

  2025cites this paper
• Netupitant Exhibits Potent Activity on Mycobacterium tuberculosis Persisters.

  2025cites this paper
• Application of antimicrobial drugs in Mycobacterium tuberculosis and research progress.

  2025cites this paper
• Granuloma Dual RNA-Seq Reveals Composite Transcriptional Programs Driven by Neutrophils and Necrosis within Tuberculous Granulomas

  2025cites this paper
• Tuberculosis and Mental Health: A Poorly Addressed Syndemic in India.

  2025cites this paper
• Motility Functions as an Essential Defense in the Bacterial Persister Lifecycle

  2025cites this paper
• Strain diversity drives heterogeneous responses to tuberculosis combination therapy

  2025cites this paper
• POLÍMEROS E SUAS TECNOLOGIAS ASSOCIADAS AO TRATAMENTO DA TUBERCULOSE: REVISÃO BIBLIOMÉTRICA E BIBLIOGRÁFICA

  2025cites this paper
• Sonoporation-enhanced the antibacterial efficacy of aminoglycosides against Gram-negative persisters

  2025cites this paper
• Mapping Nutrition and Tuberculosis Research: Insights From Bibliometric Perspective.

  2025cites this paper
• In-silico studies of anti-tuberculosis drugs using advanced computational technique: A DFT, molecular docking, and QSAR analysis

  2025cites this paper
• Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice

  2025cites this paper
• Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data

  2025cites this paper
• Insights into Natural Products from Marine-Derived Fungi with Antimycobacterial Properties: Opportunities and Challenges

  2025cites this paper
• Systems-level characterization of EGFR kinase inhibitors reveals heterogeneous effects on Mtb-macrophage interactions

  2025cites this paper
• Survival Probability in Multidrug Resistant Pulmonary Tuberculosis Patients in a South Indian Region

  2024influential citation
• Perceptions of TB-HIV comorbidity among the Nomads in Adamawa State, Nigeria

  2024cites this paper
• Adjunctive administration of parabiotic Lactobacillus sakei CVL-001 ameliorates drug-induced toxicity and pulmonary inflammation during antibiotic treatment for tuberculosis.

  2024cites this paper
• Immunostimulatory short non-coding RNAs in the circulation of patients with tuberculosis infection

  2024cites this paper
• Difficult to Treat Tuberculosis: A Challenging Vignette in Indian Context

  2024cites this paper
• Synthesis and In Vitro Antibacterial Evaluation of Mannich Base Nitrothiazole Derivatives

  2024cites this paper
• The use of Mycobacterium tuberculosis H37Ra-infected immunocompetent mice as an in vivo model of persisters.

  2024cites this paper
• Pediatric Tuberculosis: A Review of Evidence-Based Best Practices for Clinicians and Health Care Providers

  2024cites this paper
• Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis

  2024cites this paper
• Novel Prodrug Strategies for the Treatment of Tuberculosis

  2024cites this paper
• Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice

  2024cites this paper
• The rv2820c K114N mutation is related with capreomycin tolerance.

  2024cites this paper
• Elucidation of the essentiality of lumazine synthase (RibH) for Mycobacterium tuberculosis survival and discovery of potent inhibitors for enhanced antimycobacterial therapy

  2023cites this paper
• Drug-Tolerant Mycobacterium tuberculosis Adopt Different Survival Strategies in Alveolar Macrophages of Patients with Pulmonary Tuberculosis

  2023cites this paper
• Study of structurally diverse currently used and recently developed antimycobacterial drugs.

  2023cites this paper
• Natural Metabolite Ursolic Acid as an Inhibitor of Dormancy Regulator DosR of Mycobacterium tuberculosis: Evidence from Molecular Docking, Molecular Dynamics Simulation, and Free Energy Analysis.

  2023cites this paper
• Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses

  2023cites this paper
• A dose-finding study to guide use of verapamil as an adjunctive therapy in tuberculosis

  2023cites this paper
• Issues with the current drugs for Mycobacterium tuberculosis cure and potential of cell envelope proteins for new drug discovery.

  2023cites this paper
• Combination therapies: Innovative strategies for enhancing treatment outcomes

  2023cites this paper
• A Dose‐Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis

  2023cites this paper
• The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance

  2023cites this paper
• Transcriptional adaptation of Mycobacterium tuberculosis that survives prolonged multi-drug treatment in mice

  2023cites this paper
• Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis in mice

  2023cites this paper
• Advanced drug delivery and therapeutic strategies for tuberculosis treatment

  2023cites this paper
• SigH stress response mediates killing of Mycobacterium tuberculosis by activating nitronaphthofuran prodrugs via induction of Mrx2 expression

  2022cites this paper
• Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in Mycobacterium tuberculosis

  2022cites this paper
• Anti-tuberculosis treatment strategies and drug development: challenges and priorities

  2022cites this paper
• A synthesized model of tuberculosis transmission featuring treatment abandonment.

  2022cites this paper
• Failing upwards: Genetics-based strategies to improve antibiotic discovery and efficacy in Mycobacterium tuberculosis

  2022cites this paper
• Are all antibiotic persisters created equal?

  2022cites this paper
• Alkyltriphenylphosphonium turns naphthoquinoneimidazoles into potent membrane depolarizers against mycobacteria

  2022cites this paper
• Design and synthesis of novel imidazolidine-2,4-dione derivatives as InhA inhibitors: Spectral characterization, computational, and biological studies

  2022cites this paper
• Advances in the design of combination therapies for the treatment of tuberculosis

  2022cites this paper
• Eficacia y seguridad de un nuevo esquema corto para el tratamiento de la tuberculosis resistente a rifampicina. Estudio piloto

  2022cites this paper
• Trends in the Incidence of Rifampicin Resistant Mycobacterium tuberculosis Infection in Northeastern Nigeria

  2022cites this paper
• On the Hunt for Next-Generation Antimicrobial Agents: An Online Symposium Organized Jointly by the French Society for Medicinal Chemistry (Société de Chimie Thérapeutique) and the French Microbiology Society (Société Française de Microbiologie) on 9–10 December 2021

  2022cites this paper
• WhiB4 Is Required for the Reactivation of Persistent Infection of Mycobacterium marinum in Zebrafish

  2022cites this paper
• Tricyclic SpiroLactams Kill Mycobacteria In Vitro and In Vivo by Inhibiting Type II NADH Dehydrogenases

  2022cites this paper
• Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?

  2021cites this paper
• A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.

  2021cites this paper
• Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens

  2021cites this paper
• Stabilization of Hypoxia-Inducible Factor Promotes Antimicrobial Activity of Human Macrophages Against Mycobacterium tuberculosis

  2021cites this paper
• A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line tuberculosis regimen

  2021cites this paper
• Health-Promoting Benefits, Value-Added Products, and Other Uses of Banana

  2021cites this paper
• Multiform antimicrobial resistance from a metabolic mutation

  2021cites this paper
• Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV‐positive than HIV‐negative individuals: A descriptive observational study

  2021cites this paper
• Exploring the Enzymatic and Antibacterial Activities of Novel Mycobacteriophage Lysin B Enzymes

  2020cites this paper
• Human Mesenchymal Stem Cell Based Intracellular Dormancy Model of Mycobacterium tuberculosis.

  2020cites this paper
• The ongoing challenge of Pulmonary Tuberculosis in Southern Tunisia: A review of a 22-year period.

  2020cites this paper
• Sophoradiol inhibits the growth of drug resistant Mycobacterium tuberculosis in vitro and murine models of tuberculosis.

  2020cites this paper
• Rapidly Correcting Frameshift Mutations in the Mycobacterium tuberculosis orn Gene Produce Reversible Ethambutol Resistance and Small-Colony-Variant Morphology

  2020cites this paper
• Genetic and pharmacological inhibition of inflammasomes reduces the survival of Mycobacterium tuberculosis strains in macrophages

  2020cites this paper
• In Vitro Studies of Persister Cells

  2020cites this paper
• In vitro anti-mycobacterial activity of novel benzo(c)thiophene-1,3-dione: A novel scaffold against Mycobacterium tuberculosis.

  2020cites this paper
• Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds

  2020cites this paper
• Rv3131, a gene encoding nitroreductase, is essential for metronidazole activation in Mycobacterium tuberculosis under hypoxic condition

  2020cites this paper
• A biphasic nanohydroxyapatite/calcium sulphate carrier containing Rifampicin and Isoniazid for local delivery gives sustained and effective antibiotic release and prevents biofilm formation

  2020cites this paper
• Correlative light electron ion microscopy reveals in vivo localisation of bedaquiline in Mycobacterium tuberculosis–infected lungs

  2020cites this paper
• HPLC-DAD and UHPLC/QTOF-MS Analysis of Polyphenols in Extracts of the African Species Combretum padoides, C. zeyheri and C. psidioides Related to Their Antimycobacterial Activity

  2020cites this paper
• Investigating Non-sterilizing Cure in TB Patients at the End of Successful Anti-TB Therapy

  2020cites this paper
• "Microneedles for Extended Transdermal Therapeutics: A Route to Advanced Healthcare".

  2020cites this paper
• Dual Acting Small-Molecule Inhibitors Targeting Mycobacterial DNA Replication

  2019cites this paper
• Combined first line anti-TB drugs: new insights into stability

  2019cites this paper
• Discovery of Powerful Enhancers to Improve the Efficacy of Existing Antibiotics and Antimicrobials-A Strategy to Combat Bacteria Drug Resistance

  2019cites this paper
• Cell Wall Hydrolytic Enzymes Enhance Antimicrobial Drug Activity Against Mycobacterium

  2019cites this paper
• Phase variation in Mycobacterium tuberculosis glpK produces transiently heritable drug tolerance

  2019cites this paper
• Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection

  2019cites this paper
• Knowledge, Family and Social Support, Self Efficacy and Self-Care Behaviour in Pulmonary Tuberculosis Patients

  2019cites this paper
• Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial

  2019cites this paper
• Single-dose mucosal immunotherapy with chimpanzee adenovirus-based vaccine accelerates TB disease control and limits its rebound following antibiotic cessation.

  2019cites this paper
• Cutaneous tuberculosis in Rio de Janeiro, Brazil: description of a series of 75 cases

  2019cites this paper
• Digital WPI Major Qualifying Projects ( All Years ) Major Qualifying Projects April 2018 The Hunt for TB Antibiotics from the Soil

  2019cites this paper
• Synthetic Dual-Acting Small-Molecule Inhibitors That Target Mycobacterial DNA Replication

  2019cites this paper
• Treatment of Drug-Susceptible Tuberculosis.

  2019cites this paper
• Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment

  2018cites this paper
• Ursolic acid and carvacrol may be potential inhibitors of dormancy protein small heat shock protein16.3 of Mycobacterium tuberculosis

  2018cites this paper
• Characterization and elimination of stochastically generated persister subpopulation in mycobacteria

  2018cites this paper
• Molecular docking and dynamics of Nickel-Schiff base complexes for inhibiting β-lactamase of Mycobacterium tuberculosis

  2018cites this paper
• Structure and function of L,D- and D,D-transpeptidase family enzymes from Mycobacterium tuberculosis.

  2018cites this paper
• Paragonimus and paragonimiasis in West and Central Africa: unresolved questions

  2018cites this paper